Home 2017-05-08T02:45:42+00:00

Novel cancer therapies targeting key cancer pathways

READ MORE
Prescient Therapeutics PTX

We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.

prescient therapeutics

OUR COMPANY

Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

prescient therapeutics

OUR SCIENCE

Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.

prescient therapeutics

LATEST NEWS

01/02/2018Receipt of R&D Tax RebatePDF
31/01/2018December 2017 Appendix 4C - QuarterlyPDF
29/01/2017Clinical trial UpdatesPDF
10/01/2018Prescient Presenting at Biotech ShowcasePDF
20/12/2017CSO named among Top 20 Translational Researchers by NaturePDF
11/12/2017Clinical Hold Lifted on PTX-200 Breast Cancer TrialPDF